p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2751-2758

  Bottini, Alberto ^a   Berruti, Alfredo ^c   Bersiga, Alessandra ^b   Brizzi, Maria Pia ^c   Brunelli, Antonio ^a   Gorzegno, Gabriella ^c   DiMarco, Bianca ^b   Aguggini, Sergio ^a   Bolsi, Giovanna ^b   Cirillo, Fernando ^a   Filippini, Luciano ^a   Betri, Enrico ^b   Bertoli, Giovanni ^b   Alquati, Palmiro ^a   Dogliotti, Luigi ^c,d  

^a Centro di Senologia   (Italy)

^b Anatomia Patologica   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLYCOPROTEIN P; KI 67 ANTIGEN; METHOTREXATE; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; ONCOGENE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TAMOXIFEN; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033926876     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Goldie, J. H., and Coldman, A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res., 44: 3643-3653, 1984.
2. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis. Cancer (Phila.), 73: 2013-2026, 1994.
3. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
4. Raff, M. C. Social control on cell survival and cell death. Nature (Lond.), 356: 397-400, 1992.
5. Yonish-Rouach, E., Rensmitzki, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature (Lond.), 352: 345-347, 1991.
6. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
7. Evan, G. I., Willie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
8. Vaux, D. L., Cory, S., and Adams, J. bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre B-cells. Nature (Lond.), 335: 440-442, 1988.
9. Korsmeyer, S. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 80: 879-886, 1992.
10. Lotem, J., and Sachs, L. Regulation by bcl-2, c-myc, and p53 susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ., 4: 41-47, 1993.
11. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC)., 266: 807-810, 1994.
12. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zang, W. W., Owe-Schaub, and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
13. Chiba, I., Takahashi, T. A., Nau, M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., and Koga, H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.
14. Yamaguchi, A., Nakagawara, G., Kurosaka, Y., Nishimura, G., Yonemura, Y., and Miyazaki, I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br. J. Cancer, 68: 399-402, 1993.
15. Elledge, R. M., and Allred, R. C. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res. Treat., 52: 79-98, 1998.
16. Ramqvist, T., Magnusson, K. P., Wang, Y., Szekely, L., Klein, G., and Wilman, K. G. Wild-type p53 induced apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene. 8: 1495-1500, 1993.
17. Peng, H. Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M., Buchanan, J., and Goss, P. E. Mutations of the p53 gene do not occur in testis cancer. Cancer Res., 53: 3574-3578, 1993.
18. Fisher, C. J., Gillett, C. E., Vojtèšek, B., Barnes, D. M., and Millis, R. R. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer, 69: 26-31, 1994.
19. Reed, J. C. bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
20. Castle, V. P., Heidelberger, K. P., Bromberg, J., Ou, X., Dole, M., and Nunez, G. Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol., 143: 1543-1550, 1993.
21. Campos, L., Rouaoult, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P., and Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated to poor response to chemotherapy. Blood., 81: 3091-3096, 1993.
22. Gasparini, G., Barbareschi, M., Doglioni, C., Palma, P. D., Mauri, F. A., Boracchi, P., Bevilacqua, P., Caffo, O., Morelli, L., Verderio, P., Pezzella, F., and Harris, A. L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1: 189-198, 1995.
23. Joensuu, H., Pylkkanen, L., and Toikkanen, S. bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.
24. Hellemans, P., van Dam, P. A., Weyler, J., van Oosterom, A. T., Buytaert, P., and Van Marck, E. Prognostic value of bcl-2 expression in invasive breast cancer. Br. J. Cancer, 72: 354-360, 1995.
25. Elledge, R. M., Green, S., Howes, L., Clark, G. M., Berardo, M., Allred, D. C., Pugh, R., Ciocca, D., Ravdin, P., O'Sallivan, J., Rivkin, S., Martino, S., and Osborne, C. K. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. J. Clin. Oncol., 15: 1916-1922, 1997.
26. Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C., Coopmans, de Yoldi, Zucali, R., Rilke, F., Andreola, S., Silvestrini, R., Di Fronzo, G., and Valagussa, P. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst., 82: 1539-1545, 1990.
27. Bélémbaogo, E., Feillel, V., Chollet, P., Curè, H., Verrelle, P., Kwiatkowski, Achard, J. L., Le Bouedec, G., Chassagne, J., Bignon, Y. J., de Latour, M., Lafaye, C., and Dauplat, J. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur. J. Cancer, 28A: 4/5: 896-900, 1992.
28. Mauriac, L., Durand, M., Avril, A., and Dihuydy, J. M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann. Oncol., 2: 347-354, 1991.
29. Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., Margolese, R. G., Cruz, A. B., Jr., Hoehn, J. L., Lees, A. W., Dimitrov, N. V., and Bear, H. D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol., 16: 2672-2685, 1998.
30. Bonadonna, G., Valagussa, P., Brambilla, C., Ferrari, L., Molinterni, A., Terenziani, M., and Zambetti, M. Primary chemotherapy in operable breast cancer: eight-years experience at the Milan Cancer Institute. J. Clin. Oncol., 16: 93-100, 1998.
31. WHO. WHO handbook for reporting results of cancer treatment. WHO Offset Publication. Geneva, Switzerland: UICC, 1978.
32. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer; experience from a large study with long-term follow-up. Histopathology. 19: 403-410, 1991.
33. McCarty, K. S., Jr., Miller, L. S., Cox, E. B., Konrath, J., and McCarty, K. S., Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med., 109: 716-721, 1985.
34. Robertson, J. F. R., Ellis, I. O., Elston, C. V., and Blamey, R. W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-years follow-up. Eur. J. Cancer, 28: 908-910, 1992.
35. Norusis, M. J. SPSS/PC+ Base manual for the IBM PC/XT/AT and PS/2. Chicago: SPSS Inc. 1988.
36. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
37. Wang, Y., Szekely, L., Okan, I., Klein, G., and Wiman, K. G. Wild-type p53 triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene, 8: 3427-3431, 1993.
38. Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095-2097, 1994.
39. Lee, W. Y., Jin, Y. T., and Tzeng, C. C. Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Res., 16: 3007-3012, 1996.
40. Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 965-970, 1993.
41. Isola, J., Visakorpi, T., Holli, K., and Kallionemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
42. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-teleangectasia. Cell, 71: 587-597, 1992.
43. van Slooten, H. J., Clahsen, P. C., van Dierendonck, Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroide, A., van de Velde, C. J. H., and van de Vijer, M. J. Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br. J. Cancer, 74: 78-85, 1996.
44. Beck, W. T., and Dalton, W. S. Mechanisms of drug resistance. In W. T. De Vita, Jr., S. Hellman, and S. A. Rosember (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 498-512. Philadelphia: J. B. Lippincott, 1997.
45. Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G., and Schuetz, J. D. p53-dependent regulation of the MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA. 94: 11037-11042, 1997.
46. Gasparini, G. P., Toi, M., Verderio, P., Ranieri, G., Dante, S., Bonoldi, E., Boracchi, P., Fanelli, M., and Tominaga, T. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int. J. Oncol., 12: 1117-1125, 1998.
47. Degeorges, A., de Roquancourt, A., Extra, G. M., Espie, M., Bourstyn, E., de Cremoux, P., Soussi, T., and Marty, M. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res. Treat., 47: 47-55, 1998.
48. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E., and Robert, N. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J. Natl. Cancer Inst., 82: 1254-1256, 1995.
49. Clahsen, P. C., van de Velde, C. J. H., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroide, A., van den Broek, L., Sahmoud, T. M., van de Vijver, M. J. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node negative early breast cancer. J. Clin. Oncol, 16: 470-479, 1998.
50. Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., and Giaccone, G. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer, 71: 787-795, 1997.
51. Brambilla, E., Gazzeri, S., Lantuejoul, S., Coll, J. L., Moro, D., Negoescu, A., Brambilla, C. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Wafl1) in precursor bronchial lesions of lung cancer. Clin. Cancer Res., 4: 1609-1618, 1998.